Diabetic and Therapeutic Testing
Diabetes is a complex metabolic disease presently affecting millions of people worldwide with serious acute and long-term complications. Metabolic disease or syndrome (MetS) is a multifactorial condition that presents a significant challenge to public health and biomedical research. Risk factors include both genetics and the environment. For a complex disease like MetS, multiple models when used together in a complementary fashion can enable research and progress in understanding disease etiology and pathogenesis towards a cure.
Absorption Systems has worked extensively on preclinical experimental models to provide investigators with different strategies. These animal models provide the essential tools to test novel therapies, new chemical entities and medical devices for the treatment of this disease.
As a Preclinical CRO, we specialize in evaluation:
- Continuous Glucose Monitoring
- HFD/STZ-induced T2D
- Choline and L-amino acid-deficient NAFLD/NASH
- Wound healing- acute and chronic
- Diabetic retinopathy
Therapies
- Rodents ( T2D, DR, NAFLD/NASH, obesity)
- Porcine (T2D)
- Rabbit (angiogenesis diabetic retinopathy)
- Porcine hyperglycemic clamp
Diagnostics & Endpoints
- Clinical Chemistry
- Histopathology
- Blood glucose & insulin levels
- Hepatic lipid & collagen content
- Blood Gas
Fig 1: Excursion study in Yucatan Mini-pig. Adjustments of a variable glucose infusion rate (GIR) based on insulin and glucose metabolism over time.
Our team is capable of tracking multiple diabetic animals at once over various time points while maintaining variable glucose infusion rates (GIR) over time. Our team also has a great deal of experience implementing strategies to overcome inter-animal variability that can be observed over time and with different test articles.
